Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
418
Start Date
2021-08-30
Completion Date
2026-12-13
Last Updated
2026-08-28
Healthy Volunteers
No
Conditions
Interventions
SHR0302 tablets、Placebo
SHR0302 tablets dose 1 for 48 weeks
SHR0302 tablets、Placebo
SHR0302 tablets dose 2 for 48 weeks
Placebo
SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
Locations (1)
Peking University Hospital
Beijing, Beijing Municipality, China